含TPR干扰素诱导蛋白在消化系统肿瘤中作用的研究进展

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (11): 1662-1665.

含TPR干扰素诱导蛋白在消化系统肿瘤中作用的研究进展

张悦怡, 李美姿, 杨莹韵^*, 杨爱明^*

中国医学科学院北京协和医学院北京协和医院消化内科, 北京 100730

收稿日期:2020-08-04 修回日期:2020-11-20 发布日期:2021-10-27
通讯作者: *yingyunyang@126.com; yangaiming@medmail.com.cn
基金资助:
国家自然科学基金(82073184);国家重点研发计划(2016YFC1302802); 北京市科技计划(z181100001618013)

Advances in the role of interferon-induced proteins with tetratricopeptide repeats(TPR) in digestive system tumors

ZHANG Yue-yi, LI Mei-zi, YANG Ying-yun^*, YANG Ai-ming^*

Department of Gastroenterology, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730, China

Received:2020-08-04 Revised:2020-11-20 Published:2021-10-27
Contact: *yingyunyang@126.com; yangaiming@medmail.com.cn

摘要/Abstract

摘要： 本文从含TPR干扰素诱导蛋白(IFITs)的基本特征、在消化系统肿瘤中的生物学功能及其分子机制及在消化系统肿瘤诊治中的价值等方面进行综述。

关键词: 含TPR干扰素诱导蛋白(IFITs), 消化系统肿瘤, 肿瘤发生, 预后判断

Abstract: This paper reviews the basic characteristics of interferon-induced proteins with tetratricopeptide repeats(IFITs), its biological function and molecular mechanism in the development of digestive system tumors and its value in the diagnosis and treatment.

Key words: interferon-induced proteins with tetratricopeptide repeats(IFITs), digestive system tumors, tumor genesis, prognosis judgment

中图分类号:

R735

张悦怡, 李美姿, 杨莹韵, 杨爱明. 含TPR干扰素诱导蛋白在消化系统肿瘤中作用的研究进展[J]. 基础医学与临床, 2021, 41(11): 1662-1665.

ZHANG Yue-yi, LI Mei-zi, YANG Ying-yun, YANG Ai-ming. Advances in the role of interferon-induced proteins with tetratricopeptide repeats(TPR) in digestive system tumors[J]. Basic & Clinical Medicine, 2021, 41(11): 1662-1665.

参考文献

[1]Feng CX, Hong XS, Bei YA, et al. NF-κB-dependent IFIT3 induction by HBx promotes hepatitis B virus replication[J]. Front Microbiol, 2019, 10: 2382. doi: 10.3389/fmicb.2019.02382.
[2]Yuji I, Masakazu K, Bo-Ram B, et al. Hepatic IFN-induced protein with tetratricopeptide repeats regulation of HCV infection[J]. J Interferon Cytokine Res, 2019, 39: 133-146.
[3]Britney J, Laura B, Wei X, et al. Binding of IFIT1 by IFIT3 modulates protein stability and RNA binding specificity[J]. Immunity, 2018, 48: 487-499.
[4]Renata CF, Harriet VM, Xin YL, et al. IFIT3 and IFIT2/3 promote IFIT1-mediated translation inhibition by enhancing binding to non-self RNA[J]. Nucleic Acids Res, 2018, 46: 5269-5285.
[5]Nathan B, Cornelia H, Roy K, et al. Intrinsic disorder in tetratricopeptide repeat proteins[J]. Int J Mol Sci, 2020, 21: 3709. doi: 10.3390/ijms21103709.
[6]Pidugu VK, Wu MM, Yen AH, et al. IFIT1 and IFIT3 promote oral squamous cell carcinoma metastasis and contribute to the anti-tumor effect of gefitinib via enhancing p-EGFR recycling[J]. Oncogene, 2019, 38: 3232-3247.
[7]Yang YY, Zhou Y, Hou J, et al. Hepatic IFIT3 predicts interferon-alpha therapeutic response in patients of hepatocellular carcinoma[J]. Hepatology, 2017, 66: 152-166.
[8]Stawowczyk M, Van SS, Kumar KP, et al. The interferon stimulated gene 54 promotes apoptosis[J]. J Biol Chem, 2011, 286: 7257-7266.
[9]Hsu YA, Lin HJ, Sheu JJ, et al. A novel interaction between interferon-inducible protein p56 and ribosomal protein L15 in gastric cancer cells[J]. DNA Cell Biol, 2011, 30: 671-679.
[10]Jia H, Song L, Cong Q, et al. The LIM protein AJUBA promotes colorectal cancer cell survival through suppression of JAK1/STAT1/IFIT2 network[J]. Oncogene, 2017, 36: 2655-2666.
[11]Li D, Sun JJ, Liu WF, et al. Rig-G is a growth inhibitory factor of lung cancer cells that suppresses STAT3 and NF-κB[J]. Oncotarget, 2016, 7: 66032-66050.
[12]Niess H, Camaj P, Mair R, et al. Overexpression of IFN-induced protein with tetratricopeptide repeats 3 (IFIT3) in pancreatic cancer: cellular “pseudoinflammation” contributing to an aggressive phenotype[J]. Oncotarget, 2015, 20: 3306-3318.
[13]Li SX, Liu FL, Xu L, et al. Wnt/β-Catenin signaling axis is required for TFEB-mediated gastric cancer metasta-sis and epithelial-mesenchymal transition[J]. Mol Cancer Res, 2020.doi:10.1158/1541-7786.MCR-20-0180.
[14]Sylvanus K, Bulbul A, Zhou TT, et al. Scorpion venom analgesic peptide, BmK AGAP inhibits stemness, and epithelial-mesenchymal transition by down-regulating PTX3 in breast cancer[J]. Front Oncol, 2019, 9: 21. doi: 10.3389/fonc.2019.00021. eCollection 2019.
[15]Lai KC, Liu CJ, Chang KW, et al. Depleting IFIT2 mediates atypical PKC signaling to enhance the migration and metastatic activity of oral squamous cell carcinoma cells[J]. Oncogene, 2013, 32: 3686-3697.
[16]Chen L, Liu S, Xu F, et al. Inhibition of proteasome activity induces aggregation of IFIT2 in the centrosome and enhances IFIT2-induced cell apoptosis[J]. Int J Biol Sci, 2017, 13: 383-390.
[17]Zhang BH, Tang BF, Gao JY, et al. A hypoxia-related signature for clinically predicting diagnosis, prognosis and immune microenvironment of hepatocellular carcinoma patients[J]. J Transl Med, 2020, 18: 342. doi: 10.1186/s12967-020-02492-9.
[18]Andreas AH, Ulf G, Christine G, et al. IL7-IL12 engineered mesenchymal stem cells (MSCs) improve a CART cell attack against colorectal cancer cells[J]. Cells, 2020, 9: 873. doi: 10.3390/cells9040873.
[19]KIM W, KHAN SK, LIU Y, et al. Hepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma[J]. Gut, 2018, 67:1692-1703.
[20]Wang JH, Dai M, Cui YG, et al. Association of abnormal elevations in IFIT3 with overactive cyclic GMP-AMP synthase/stimulator of interferon genes signaling in human systemic lupus erythematosus monocytes[J]. Arthritis Rheumatol, 2018, 70: 2036-2045.
[21]Chen LJ, Zhai WS, Zheng X, et al. Decreased IFIT2 expression promotes gastric cancer progression and predicts poor prognosis of the patients[J]. Cell Physiol Biochem, 2018, 45: 15-25.
[22]Zhao Y, Altendorf-Hofmann A, Pozios I, et al. Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma[J]. J Cancer Res Clin Oncol, 2017, 143: 1061-1068.